RAC

2.20%

$1.78 race oncology ltd

Ann: Race releases complete cardio-protection data & video, page-139

First 139 Last

Share
Profile

Follow
Boffin99

2,842 Posts.

2892

03/06/23

20:13

Post #: 68116915
Share

Originally posted by Boffin99: ↑

Cardio Protection and Anti-Cancer;

My view on the Mechanism of Action of what is going on;

1. Bisantrene is a magnet to iron.

2. Cardiotoxicity is caused by iron dependent functions such as oxidative stress and ROS production.

3. By binding tightly to iron, Bisantrene reduces the iron that feeds Cardiotoxicity.

4. Basically, Bisantrene is the ‘Cookie Monster’ and iron is the ‘Cookie’. Without the cookie there is no cardiotoxicity.

5. But Oxidative stress can help kill cancer so reducing this can reduce anti-cancer effects.

6. Some good news, healthy cells counteract oxidative stress at a superior rates to cancer cells.

7. Whilst Oxidative stress is sufficiently reduced for healthy cells to be protected, cancer cells remain unprotected.

8. Bisantrene therefore hits the sweet spot where it retains cardio protection and anti-cancer effects.

9. At high doses Bisantrene acts relies on its Anthracycline effects to kill cancer.

10. At low doses Bisantrene is relies on its super power as an FTO inhibitor (binding to the catalytic pocket of FTO).

11. FTO overexpression correlates to the growth of 30+ cancers and also linked to drug resistance.

12. Reducing FTO expression can stop the growth of cancer and helps kill treatment resistance tumours.

13. Bisantrene is additive and synergenistic with other standard of care treatments.

There is definitely a lot of luck involved with Bisantrene. Starting off as a legacy chemo drug for AML. Now extending to a potential platform drug as the worlds first FTO inhibitor in the clinic and cardio-protective anti-cancer solution.

#Disrupting Cardio-oncology 2023

Expand

https://doi.org/10.3389/fphys.2014.00084

the Iron, Oxidative stress, ROS related cardio protective narrative also explains why the Red Blood Cell count doesn’t reduce, which is normally the result of anthracyclines.

https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-021-01074-1

also why anti cancer effect isn’t lost due to lowering oxidative stress and free radicals is metabolised differently in healthy cells v cancer cells, which are impacted more.

another piece of the puzzle.

RAC Price at posting: $1.43 Sentiment: Buy Disclosure: Held
23 Upvote

2 Great analysis

Reply

Top Stories

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The market's shrugged at China's stimulus measures all year. Why is this one different?

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

The winners & losers on market if negative gearing were gone

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 98 more messages in this thread...

First 139 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.78		Change -0.040(2.20%)		Mkt cap ! $302.5M

Open	High	Low	Value	Volume
$1.81	$1.82	$1.76	$132.8K	74.40K

Buyers (Bids)

No.	Vol.	Price($)
1	170	$1.77

Sellers (Offers)

Price($)	Vol.	No.
$1.78	2	1

View Market Depth

No.	Vol.	Price($)
1	170	1.765
2	4000	1.755
3	12714	1.750
1	3000	1.740
1	1405	1.720

Price($)	Vol.	No.
1.775	2	1
1.780	3781	1
1.820	2315	1
1.830	7500	1
1.840	1000	1

Last trade - 16.10pm 27/09/2024 (20 minute delay)

RAC (ASX) Chart

Ann: Race releases complete cardio-protection data & video, page-139

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The market's shrugged at China's stimulus measures all year. Why is this one different?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACCC seeks Olam divestments before it can buy Namoi Cotton

The winners & losers on market if negative gearing were gone

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Race releases complete cardio-protection data & video, page-139

Top Stories

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The market's shrugged at China's stimulus measures all year. Why is this one different?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACCC seeks Olam divestments before it can buy Namoi Cotton

The winners & losers on market if negative gearing were gone

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News